Health Biotech Limited WHO-GMP
Health Biotech Limited
Health Biotech Limited Health Biotech Limited
Health Biotech Limited Health Biotech Limited

Health Biotech Limited
Home - Products - Oncology(Anti-Cancer-Injectables) - Topotecan Injection

Topotecan Injection

Category: Antineoplastic
Composition- : Each vial contains: Topotecan HCl equivalent to Topotecan 2.5mg/2.5ml, 4mg/4ml.
Topotecan is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death). Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream ( 1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor.

Specification- Light Greenish color powder filled in glass vials.
pH------------ 2.5 to 4.5
Indication : Metastatic carcinoma of the ovary after failure of initial or subsequent chemo therapy. Small cell lung cancer disease after failure of first line chemotherapy
Dosage :- The recommended starting dose is 1.5mg/m2 body surface area by IV infusion over 30 minutes daily for 5 consecutive days In absence of tumor progression, a minimum of four courses are recommended, as tumour response may be delayed.
Contraindications:- Severe hypersensitivity reactions (e.g., anaphylactoid reactions)
Pregnant or Breastfeeding,
Severe bone marrow depression.
Precautions:- Bone Marrow Suppression, Thrombocytopenia, Diarrhea, Interstitial Lung Disease, Pregnancy Neutropenia, Thrombocytopenia, Anemia.
Drug interaction: Cyclosporine A (inhibitor of ABCB1, ABCC1 [MRP-1], and CYP3A4) with hycamtin capsules increased topotecan exposure to 2- to 3-fold of control. The pharmacokinetics of topotecan were generally unchanged when coadministered with ranitidine.
Adverse Effect-: Bone marrow suppression. Primarily neutropenia, thrombocytopenic anaemia, abdominal discomfort.
Storage: Store between 2-80C
Purity:- Not less than 99.5%.
» Get an Instant Quote

Topotecan Injection
Ask for Price
Health Biotech Limited
Our Products
Oncology(Anti-Cancer-Injectables)  |   Pre-Filled Syringes  |   Anti-Infectives Injections   |   Liquid Ampoules / Vials  |   Biological Injections
Cardiovascular Injections  |   Neurology  |   Other Injectables  |   Hormones  |   Eye/ Ear/ Nasal Drops  |   Liquid Syrups, Dry Syrups & Redi-Mix Syrups  |   Pharmaceutical Capsules  |   Pharmaceutical Tablets  |   Tablets and Capsule  |   Green Tea Fat Burner

Clicky Web Analytics

Looking for Product Name ?